Evidence map›Paper›PMID 37768472›Full record

ArticleJournal of neuro-oncology2023

Advancing personalized prognosis in atypical and anaplastic meningiomas through interpretable machine learning models.

Mert Karabacak, Pemla Jagtiani, Alejandro Carrasquilla, Raj K Shrivastava, Konstantinos Margetis

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mert KarabacakDepartment of Neurosurgery, Mount Sinai Health System, New York, NY, USA.
Pemla JagtianiSchool of Medicine, SUNY Downstate Health Sciences University, New York, NY, USA.
Alejandro CarrasquillaDepartment of Neurosurgery, Mount Sinai Health System, New York, NY, USA.
Raj K ShrivastavaDepartment of Neurosurgery, Mount Sinai Health System, New York, NY, USA.
Konstantinos MargetisDepartment of Neurosurgery, Mount Sinai Health System, New York, NY, USA. Konstantinos.Margetis@mountsinai.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe primary purpose of this study was to utilize machine learning (ML) models to create a web application that can predict survival outcomes for patients diagnosed with atypical and anaplastic meningiomas.

methodsIn this retrospective cohort study, patients diagnosed with WHO grade II and III meningiomas were selected from the National Cancer Database (NCDB) to analyze survival outcomes at 12, 36, and 60 months. Five machine learning algorithms - TabPFN, TabNet, XGBoost, LightGBM, and Random Forest were employed and optimized using the Optuna library for hyperparameter tuning. The top-performing models were then deployed into our web-based application.

resultsFrom the NCDB, 12,197 adult patients diagnosed with histologically confirmed WHO grade II and III meningiomas were retrieved. The mean age was 61 (± 20), and 6,847 (56.1%) of these were females. Performance evaluation indicated that the top-performing models for each outcome were the models built with the TabPFN algorithm. The TabPFN models yielded area under the receiver operating characteristic (AUROC) values of 0.805, 0.781, and 0.815 in predicting 12-, 36-, and 60-month mortality, respectively.

conclusionWith the continuous growth of neuro-oncology data, ML algorithms act as key tools in predicting survival outcomes for WHO grade II and III meningioma patients. By incorporating these interpretable models into a web application, we can practically utilize them to improve risk evaluation and prognosis for meningioma patients.

Indexed as

Meningeal NeoplasmsMeningiomaAdultFemaleHumansMachine LearningMaleMiddle AgedPrognosisRetrospective StudiesArtificial intelligenceMachine learningMeningiomaPersonalized medicineSurvivalWeb application

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.